DMK Pharmaceuticals Corporation
CY3B
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 134.95% | 543.64% | 153.58% | 113.76% | -62.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 134.95% | 543.64% | 153.58% | 113.76% | -62.50% |
| Cost of Revenue | -9.06% | 16.63% | 1.79% | -8.58% | -16.53% |
| Gross Profit | 65.60% | 74.67% | 67.32% | 68.90% | -60.92% |
| SG&A Expenses | -0.21% | -14.43% | -8.50% | -17.94% | -45.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.73% | -31.82% | -19.62% | -12.74% | -25.97% |
| Operating Income | 39.64% | 45.18% | 30.05% | 21.71% | 21.87% |
| Income Before Tax | 30.88% | 24.81% | 18.93% | 24.15% | 20.70% |
| Income Tax Expenses | 150.00% | 150.00% | 150.00% | 150.00% | -66.67% |
| Earnings from Continuing Operations | 30.88% | 24.80% | 18.93% | 24.15% | 20.70% |
| Earnings from Discontinued Operations | 18.28% | 81.49% | 99.57% | 97.53% | 91.93% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.36% | 36.71% | 38.57% | 42.22% | 41.86% |
| EBIT | 39.64% | 45.18% | 30.05% | 21.71% | 21.87% |
| EBITDA | 38.71% | 45.71% | 30.78% | 22.89% | 22.41% |
| EPS Basic | 38.10% | 40.61% | 39.31% | 45.30% | 53.06% |
| Normalized Basic EPS | 56.86% | 53.42% | 25.68% | 40.48% | 40.28% |
| EPS Diluted | 38.15% | 40.64% | 39.35% | 44.72% | 52.64% |
| Normalized Diluted EPS | 56.86% | 53.42% | 25.68% | 40.48% | 40.28% |
| Average Basic Shares Outstanding | 63.28% | 5.90% | 1.03% | 3.99% | 14.87% |
| Average Diluted Shares Outstanding | 63.28% | 5.90% | 1.03% | 3.99% | 14.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |